118 related articles for article (PubMed ID: 12509385)
1. Myelodysplastic subclones in chronic myeloid leukemia: implications for imatinib mesylate therapy.
Goldberg SL; Madan RA; Rowley SD; Pecora AL; Hsu JW; Tantravahi R
Blood; 2003 Jan; 101(2):781. PubMed ID: 12509385
[No Abstract] [Full Text] [Related]
2. Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate.
Mesa RA; Steensma DP; Hoyer J; Ketterling RP
Br J Haematol; 2003 Oct; 123(2):366-7. PubMed ID: 14531922
[No Abstract] [Full Text] [Related]
3. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority.
Bumm T; Müller C; Al-Ali HK; Krohn K; Shepherd P; Schmidt E; Leiblein S; Franke C; Hennig E; Friedrich T; Krahl R; Niederwieser D; Deininger MW
Blood; 2003 Mar; 101(5):1941-9. PubMed ID: 12411298
[TBL] [Abstract][Full Text] [Related]
4. Myelodysplastic features developing in Philadephia-negative cells during imatinib mesylate therapy for CML: report of a new case.
Mozziconacci MJ; Caillères S; Maurice C; Vey N; Sainty D; Blaise D; Lafage-Pochitaloff M
Leukemia; 2003 Sep; 17(9):1901-2. PubMed ID: 12970792
[No Abstract] [Full Text] [Related]
5. Emergence of abnormal clone with monsomy 7 in Philadelphia negative cells of CML patients treated with tyrosine kinase inhibitors.
de Mello Conchon MR; Bendit I; Ferreira P; Lima W; Kumeda C; Dias L; de Alencar Fischer Chamone D; Dorlhiac-Llacer PE
Int J Hematol; 2009 Jan; 89(1):123-125. PubMed ID: 19093165
[No Abstract] [Full Text] [Related]
6. Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones.
Chee YL; Vickers MA; Stevenson D; Holyoake TL; Culligan DJ
Leukemia; 2003 Mar; 17(3):634-5. PubMed ID: 12646955
[No Abstract] [Full Text] [Related]
7. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
[TBL] [Abstract][Full Text] [Related]
8. Complete cytogenetic and molecular response to treatment with imatinib mesylate for philadelphia chromosome positive acute myeloid leukemia with multilineage dysplasia.
Ueda K; Horiike S; Zen K; Misawa S; Taniwaki M
Leuk Lymphoma; 2006 Sep; 47(9):1967-9. PubMed ID: 17065015
[No Abstract] [Full Text] [Related]
9. How complete is "complete" molecular response in imatinib-treated chronic myeloid leukemia?
Ross DM; Hughes TP
Leuk Lymphoma; 2008 Jul; 49(7):1230-1. PubMed ID: 18604711
[No Abstract] [Full Text] [Related]
10. Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate.
Vega-Ruiz A; O'Brien S; Cortes J; Kebriaei P; Thomas D; Kantarjian H; Ravandi F
Leuk Res; 2008 Sep; 32(9):1468-71. PubMed ID: 18355919
[TBL] [Abstract][Full Text] [Related]
11. [Particular evolution of complex cytogenetic variants of chronic myeloid leukemia treated with imatinib].
Sawadogo S; Hien FM; Béogo R; Toguyeni A; Ouédraogo GA
Pan Afr Med J; 2013; 15():132. PubMed ID: 24319522
[TBL] [Abstract][Full Text] [Related]
12. Molecular monitoring in chronic myeloid leukemia patients who achieve complete cytogenetic remission on imatinib.
Lin F; Drummond M; O'Brien S; Cervantes F; Goldman J; Kaeda J
Blood; 2003 Aug; 102(3):1143. PubMed ID: 12869491
[No Abstract] [Full Text] [Related]
13. Insufficient outcomes with imatinib mesylate: case report of Ph-positive acute myeloid leukemia evolving from myelodysplastic syndrome.
Isoda A; Nakahashi H; Hoshino T; Mitsui T; Yoshida Y
Am J Hematol; 2007 Jun; 82(6):501-2. PubMed ID: 17301971
[No Abstract] [Full Text] [Related]
14. Chronic lymphocytic leukaemia developing in the course of chronic myeloid leukaemia.
Salim R; Wang L; Lin K; Clark RE
Leuk Lymphoma; 2002 Nov; 43(11):2225-7. PubMed ID: 12533052
[TBL] [Abstract][Full Text] [Related]
15. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.
Press RD; Love Z; Tronnes AA; Yang R; Tran T; Mongoue-Tchokote S; Mori M; Mauro MJ; Deininger MW; Druker BJ
Blood; 2006 Jun; 107(11):4250-6. PubMed ID: 16467199
[TBL] [Abstract][Full Text] [Related]
16. Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate.
Aleem A; Siddiqui N
Leuk Lymphoma; 2005 Jul; 46(7):1097-9. PubMed ID: 16019565
[TBL] [Abstract][Full Text] [Related]
17. Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate.
Matsuda M; Morita Y; Shimada T; Miyatake J; Hirase C; Tanaka M; Tatsumi Y; Maeda Y; Kanamaru A
Int J Hematol; 2005 May; 81(4):307-9. PubMed ID: 15914360
[TBL] [Abstract][Full Text] [Related]
18. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.
Kovitz C; Kantarjian H; Garcia-Manero G; Abruzzo LV; Cortes J
Blood; 2006 Oct; 108(8):2811-3. PubMed ID: 16809614
[TBL] [Abstract][Full Text] [Related]
19. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.
Chu S; Xu H; Shah NP; Snyder DS; Forman SJ; Sawyers CL; Bhatia R
Blood; 2005 Mar; 105(5):2093-8. PubMed ID: 15345592
[TBL] [Abstract][Full Text] [Related]
20. Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era.
Goldman J
Curr Opin Hematol; 2005 Jan; 12(1):33-9. PubMed ID: 15604889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
